Apixaban and rivaroxaban use for atrial fibrillation in patients with obesity and BMI ≥50 kg/m2.
Cavan P O'KaneJuan Carlo O AvalonJordan L LacosteWei FangChristopher M BiancoLaura DavissonKara L PiechowskiPublished in: Pharmacotherapy (2021)
This study demonstrated that apixaban and rivaroxaban in patients with a BMI ≥50 kg/m2 for treatment of NVAF may be safe and effective at preventing thromboembolic events and had no increased risk of bleeding. Although, findings should be interpreted with caution and confirmed with additional studies. This study contributes to the growing body of evidence that direct oral anticoagulants (DOACs) may be effective and safe to use for the treatment of NVAF in patients with BMI ≥50 kg/m2 .
Keyphrases
- atrial fibrillation
- direct oral anticoagulants
- venous thromboembolism
- oral anticoagulants
- left atrial
- catheter ablation
- left atrial appendage
- body mass index
- heart failure
- weight gain
- insulin resistance
- pulmonary embolism
- metabolic syndrome
- combination therapy
- skeletal muscle
- physical activity
- acute coronary syndrome
- mitral valve
- left ventricular